Brokers Offer Predictions for Prestige Consumer Healthcare Inc.’s Q1 2025 Earnings (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for Prestige Consumer Healthcare in a report issued on Wednesday, June 12th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.91 per share for the quarter, down from their previous estimate of $0.92. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.42 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q2 2025 earnings at $1.12 EPS, FY2025 earnings at $4.42 EPS, Q2 2026 earnings at $1.15 EPS and Q4 2026 earnings at $1.24 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by ($0.12). Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. The firm had revenue of $277.00 million for the quarter, compared to analyst estimates of $287.42 million. During the same period last year, the firm earned $1.07 EPS. The company’s quarterly revenue was down 3.1% compared to the same quarter last year.

PBH has been the subject of a number of other reports. DA Davidson reissued a “neutral” rating and issued a $65.00 price target on shares of Prestige Consumer Healthcare in a report on Thursday, May 16th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 21st. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.25.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $64.35 on Thursday. The stock’s 50 day moving average price is $67.46 and its 200 day moving average price is $66.03. The firm has a market cap of $3.21 billion, a P/E ratio of 15.43, a PEG ratio of 1.87 and a beta of 0.50. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 3.20. Prestige Consumer Healthcare has a 1 year low of $56.25 and a 1 year high of $75.31.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $25,000. Pacer Advisors Inc. raised its stake in shares of Prestige Consumer Healthcare by 85.7% during the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after purchasing an additional 204 shares during the period. Provence Wealth Management Group bought a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the last quarter. Finally, Principal Securities Inc. acquired a new position in Prestige Consumer Healthcare in the fourth quarter worth about $29,000. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.